125 related articles for article (PubMed ID: 29786107)
1. E3 ubiquitin ligase Hakai regulates cell growth and invasion, and increases the chemosensitivity to cisplatin in non‑small‑cell lung cancer cells.
Liu Z; Wu Y; Tao Z; Ma L
Int J Mol Med; 2018 Aug; 42(2):1145-1151. PubMed ID: 29786107
[TBL] [Abstract][Full Text] [Related]
2. FBW7 upregulation enhances cisplatin cytotoxicity in non- small cell lung cancer cells.
Yu HG; Wei W; Xia LH; Han WL; Zhao P; Wu SJ; Li WD; Chen W
Asian Pac J Cancer Prev; 2013; 14(11):6321-6. PubMed ID: 24377525
[TBL] [Abstract][Full Text] [Related]
3. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
6. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.
Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113
[TBL] [Abstract][Full Text] [Related]
7. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
[TBL] [Abstract][Full Text] [Related]
8. Phloretin exhibits an anticancer effect and enhances the anticancer ability of cisplatin on non-small cell lung cancer cell lines by regulating expression of apoptotic pathways and matrix metalloproteinases.
Ma L; Wang R; Nan Y; Li W; Wang Q; Jin F
Int J Oncol; 2016 Feb; 48(2):843-53. PubMed ID: 26692364
[TBL] [Abstract][Full Text] [Related]
9. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
10. Hakai overexpression effectively induces tumour progression and metastasis in vivo.
Castosa R; Martinez-Iglesias O; Roca-Lema D; Casas-Pais A; Díaz-Díaz A; Iglesias P; Santamarina I; Graña B; Calvo L; Valladares-Ayerbes M; Concha Á; Figueroa A
Sci Rep; 2018 Feb; 8(1):3466. PubMed ID: 29472634
[TBL] [Abstract][Full Text] [Related]
11. miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.
Zhang Z; Zhang L; Yin ZY; Fan XL; Hu B; Wang LQ; Zhang D
Int J Clin Exp Pathol; 2014; 7(10):7236-41. PubMed ID: 25400821
[TBL] [Abstract][Full Text] [Related]
12. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.
Wang S; Pan H; Liu D; Mao N; Zuo C; Li L; Xie T; Huang D; Huang Y; Pan Q; Yang L; Wu J
Int J Oncol; 2015 Feb; 46(2):809-17. PubMed ID: 25434755
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42.
Yang T; Chen T; Li Y; Gao L; Zhang S; Wang T; Chen M
Tumour Biol; 2015 Mar; 36(3):1903-11. PubMed ID: 25432132
[TBL] [Abstract][Full Text] [Related]
14. DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Li J; Yu T; Yan M; Zhang X; Liao L; Zhu M; Lin H; Pan H; Yao M
Exp Cell Res; 2019 Jan; 374(2):304-314. PubMed ID: 30528265
[TBL] [Abstract][Full Text] [Related]
15. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment.
Li Q; Yang Z; Chen M; Liu Y
Int J Mol Med; 2016 Apr; 37(4):1067-74. PubMed ID: 26936095
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
18. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
19. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
20. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]